Literature DB >> 10080104

Further characterization of the autoantibody response of Palmerston North mice.

B S Handwerger1, C E Storrer, C S Wasson, F Movafagh, M Reichlin.   

Abstract

PN mice spontaneously develop, with age, a lupus-like disease. The present study further evaluated autoantibody production in female PN mice. As early as 1 month of age, all PN mice had detectable IgM antibodies to dsDNA and ssDNA and two-thirds produced IgM anticardiolipin antibodies. By 3 months of age, all PN mice exhibited evidence of isotype switch in their autoantibody response; 88-100% had serum IgG antibodies to ssDNA and dsDNA, respectively. By 6-12 months of age, essentially all female PN mice had IgG antibodies to ssDNA, dsDNA, cardiolipin and other phospholipids (PS, PC, PI, and PG), and IgG and 63% produced IgG anti-mouse erythrocyte antibodies. In addition, 50-100% produced IgA antibodies to dsDNA and ssDNA, and one-third produced IgA anti-IgG antibodies. Antibodies to U1RNP and Sm were present in 81% of 6- to 12-month-old PN mice and 39-94% had IgG or IgM antibodies to mouse thymocytes. Although all four IgG isotypes were represented in the anti-dsDNA response, IgG1 antibodies dominated the IgG anticardiolipin response. The presence of IgA autoantibodies and the predominance of IgG1 in the IgG anticardiolipin response suggest that IL-4 and either IL-5 and/or TGF-beta serve as B cell stimulatory cytokines for autoreactive B cells in PN mice.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10080104     DOI: 10.1023/a:1020514602141

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  72 in total

Review 1.  Anti-Sm autoantibodies in systemic lupus erythematosus mice: a model system for disease-specific autoreactivity.

Authors:  R A Eisenberg
Journal:  Springer Semin Immunopathol       Date:  1992

Review 2.  Cellular events associated with the immunogenesis of anti-erythrocyte autoantibody responses of NZB mice.

Authors:  D H Deheer; T S Edginton
Journal:  Transplant Rev       Date:  1976

3.  Vasculitis in the Palmerston North mouse model of lupus: phenotype and cytokine production profile of infiltrating cells.

Authors:  I G Luzina; R H Knitzer; S P Atamas; W C Gause; J C Papadimitriou; M B Sztein; C E Storrer; B S Handwerger
Journal:  Arthritis Rheum       Date:  1999-03

4.  Palmerston North mice, a new animal model of systemic lupus erythematosus.

Authors:  S E Walker; R H Gray; M Fulton; R D Wigley; B Schnitzer
Journal:  J Lab Clin Med       Date:  1978-12

5.  Serum-serum interactions in autoimmune mice.

Authors:  R A Eisenberg; L T Thor; F J Dixon
Journal:  Arthritis Rheum       Date:  1979-10

6.  Chronic graft versus host disease-associated autoimmune manifestations are independently regulated by different MHC class II loci.

Authors:  D S Bradley; J C Jennette; P L Cohen; R A Eisenberg
Journal:  J Immunol       Date:  1994-02-15       Impact factor: 5.422

7.  Resistance to therapy in mature Palmerston North mice treated with cyclophosphamide or hydrocortisone sodium succinate.

Authors:  S E Walker; B Schnitzer
Journal:  Arthritis Rheum       Date:  1980-05

8.  Natural thymocytotoxic autoantibody and reactive antigen in New Zealand black and other mice.

Authors:  T Shirai; R C Mellors
Journal:  Proc Natl Acad Sci U S A       Date:  1971-07       Impact factor: 11.205

9.  Pattern of anti-small nuclear ribonucleoprotein antibodies in MRL/Mp-lpr/lpr mice suggests that the intact U1 snRNP particle is their autoimmunogenic target.

Authors:  S Fatenejad; W Brooks; A Schwartz; J Craft
Journal:  J Immunol       Date:  1994-06-01       Impact factor: 5.422

10.  Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains.

Authors:  B S Andrews; R A Eisenberg; A N Theofilopoulos; S Izui; C B Wilson; P J McConahey; E D Murphy; J B Roths; F J Dixon
Journal:  J Exp Med       Date:  1978-11-01       Impact factor: 14.307

View more
  1 in total

1.  Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity.

Authors:  A Shustov; I Luzina; P Nguyen; J C Papadimitriou; B Handwerger; K B Elkon; C S Via
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.